Safety of hormone replacement therapy after mastectomy

Christopher B. Del Mar*, Paul P. Glasziou, Anneliese B. Spinks, Sharon L. Sanders, Deborah J. Hilton

*Corresponding author for this work

Research output: Contribution to journalShort surveyResearchpeer-review


Clinical question
After mastectomy, chemotherapy and radiotherapy for high-grade ductal carcinoma with nodal involvement and lymphatic infiltration, a 48-year-old woman had premature menopause, with symptoms of loss of libido. Her general practitioner wanted to know how safe and effective hormone replacement therapy (HRT) would be for this patient.

Search question
The revised question was: “Does HRT increase the likelihood of recurrence in a patient previously diagnosed with breast cancer?”.

The ideal study to answer this question would be a randomised controlled trial of HRT versus placebo comparing outcomes of mortality and recurrence in women previously treated for breast cancer or high-grade ductal carcinoma of the breast.
Original languageEnglish
Pages (from-to)285
Number of pages1
JournalMedical Journal of Australia
Issue number6
Publication statusPublished - 18 Mar 2002
Externally publishedYes


Dive into the research topics of 'Safety of hormone replacement therapy after mastectomy'. Together they form a unique fingerprint.

Cite this